Evidence map›Paper›PMID 40131608›Full record

ReviewEJNMMI radiopharmacy and chemistry2025

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

S Spreckelmeyer, J Dasilva, C Decristoforo, R H Mach, J Passchier, G Carlucci, M Al Qahtani, A Duatti, B T Cornelissen, J Engle and 14 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

S SpreckelmeyerDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt- Universität zu Berlin, Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. sarah.spreckelmeyer@charite.de.ORCID http://orcid.org/0000-0003-1348-0309
J DasilvaUniversity of Montreal, Montreal, Canada.
C DecristoforoMedical University Innsbruck, Innsbruck, Austria.
R H MachUniversity of Pennsylvania, Philadelphia, USA.
J PasschierInvicro London, London, UK.
G CarlucciUniversity of California, Los Angeles, CA, USA.
M Al QahtaniCyclotron and Radiopharmaceuticals Department, Research & Innovation, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
A DuattiUniversity of Ferrara, Ferrara, Italy.
B T CornelissenOxford University, Oxford, UK.
J EngleUniversity of Wisconsin, Madison, WI, USA.
A DenkovaDelft University of Technology, Delft, Netherlands.
J J M A HendrikxNKI, Amsterdam, The Netherlands.
Y SeimbilleErasmus MC, Rotterdam, Netherlands.
X YangPeking University First Hospital, Beijing, China.
H JiaBeijing Normal University, Beijing, China.
M-R ZhangNational Institutes for Quantum Science and Technology, Chiba, Japan.
M YangJiangsu Institute of Nuclear Medicine, Jiangsu, China.
L PerkRadboud University Medical Center Nijmegen, Nijmegen, Netherlands.
P CaravanMassuchusetts General Hospital, Harvard University, Boston, USA.
P LavermanRadboud Medical Center, Nijmegen, Netherlands.
Z ChengShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
C HoehrTRIUMF, Vancouver, BC, Canada.
T SakrEgyptian Atomic Energy Authority, Cairo, Egypt.
J R ZeevaartNecsa, Pretoria, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development and application of radiopharmaceuticals. MAIN BODY: This selection of highlights provides commentary on 24 different topics selected by each co-authoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Indexed as

Highlight articlesNuclear medicineRadiochemistryRadiopharmaceutical sciencesRadiopharmacy

Identifiers

PMID40131608
PMCPMC11936851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.